April 9, 2018 07:12 AM EDT
R&D

Mer­ck racks up an­oth­er win in wide-rang­ing PhI­II Keytru­da lung can­cer study, this time as so­lo ther­a­py

John Carroll

Editor & Founder

Mer­ck $MRK has scored an­oth­er big win in its broad range of piv­otal Keytru­da stud­ies in lung can­cer.

This morn­ing in­ves­ti­ga­tors re­port that KEYNOTE-042

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

ADC sci­en­tist who paved the way for Dai­ichi’s En­her­tu dies

As­traZeneca re­veals first clin­i­cal da­ta for bis­pe­cif­ic T cell en­gager from TeneoT­wo buy­out

Biose­cure bill is left out of end-of-year de­fense pack­age, deal­ing blow to chances

Beam shares re­sults from sev­en pa­tients who re­ceived gene-edit­ed sick­le cell ther­a­py

Dutch biotech nabs €85M to po­si­tion in­flam­ma­to­ry an­ti­body for a phar­ma buy­er

sponsored

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

A service from the Financial Times